5 Most Promising Psychedelic Stocks According to Hedge Funds

3. Sage Therapeutics, Inc. (NASDAQ:SAGE)

Number of Hedge Fund Investors In Q3 2023: 25

Sage Therapeutics, Inc. (NASDAQ:SAGE) is an American firm developing treatments for a wide variety of diseases such as bipolar depression, Huntington’s Disease, and others. Its shares are rated Buy on average and analysts have set an average share price target of $25.17.

As of September 2023, 25 out of the 910 hedge funds surveyed by Insider Monkey had bought and owned Sage Therapeutics, Inc. (NASDAQ:SAGE)’s shares. William Leland Edwards’s Palo Alto Investors was the largest shareholder courtesy of its $20.6 million stake.

Follow Sage Therapeutics Inc. (NASDAQ:SAGE)